Published in Clin Pharmacol Ther on March 01, 2007
Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther (2008) 11.67
The emergence of lncRNAs in cancer biology. Cancer Discov (2011) 6.32
Bioinformatics challenges for personalized medicine. Bioinformatics (2011) 2.28
PharmGKB: understanding the effects of individual genetic variants. Drug Metab Rev (2008) 2.09
Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics (2010) 1.91
Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin Pharmacol Ther (2014) 1.73
The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics. Bioinform Biol Insights (2008) 1.73
Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A (2008) 1.47
SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res (2009) 1.46
SNPeffect 4.0: on-line prediction of molecular and structural effects of protein-coding variants. Nucleic Acids Res (2011) 1.44
Integrating Epigenomics into Pharmacogenomic Studies. Pharmgenomics Pers Med (2008) 1.18
Genetic mechanisms of atrial fibrillation: impact on response to treatment. Nat Rev Cardiol (2013) 1.11
Improvements to bead-based oligonucleotide ligation SNP genotyping assays. Biotechniques (2008) 1.04
Dopamine genes and nicotine dependence in treatment-seeking and community smokers. Neuropsychopharmacology (2009) 1.04
Desiderata for computable representations of electronic health records-driven phenotype algorithms. J Am Med Inform Assoc (2015) 1.04
PharmGKB: an integrated resource of pharmacogenomic data and knowledge. Curr Protoc Bioinformatics (2008) 1.03
Cardiovascular pharmacogenomics. Circ Res (2011) 1.03
Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine. Am J Drug Alcohol Abuse (2009) 1.02
Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5). J Pharmacol Exp Ther (2009) 1.01
Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J (2012) 1.00
K(ATP) channel pharmacogenomics: from bench to bedside. Clin Pharmacol Ther (2007) 0.97
Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. J Pharmacol Exp Ther (2010) 0.96
Chapter 7: Pharmacogenomics. PLoS Comput Biol (2012) 0.96
Candidate gene association studies: a comprehensive guide to useful in silico tools. BMC Genet (2013) 0.95
Ontology-guided data preparation for discovering genotype-phenotype relationships. BMC Bioinformatics (2008) 0.93
Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des (2009) 0.93
Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records. Pharmacogenomics (2013) 0.91
Peax: interactive visual analysis and exploration of complex clinical phenotype and gene expression association. Pac Symp Biocomput (2015) 0.90
Pharmacogenomics of chemotherapeutic susceptibility and toxicity. Genome Med (2012) 0.89
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. Invest New Drugs (2011) 0.88
Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity. Trends Cancer Res (2008) 0.87
Long non-coding RNAs in haematological malignancies. Int J Mol Sci (2013) 0.83
Subtypes of alpha1-adrenoceptors in BPH: future prospects for personalized medicine. Nat Clin Pract Urol (2009) 0.82
Progress towards the integration of pharmacogenomics in practice. Hum Genet (2014) 0.81
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity. BMC Cancer (2015) 0.81
Conditional entropy in variation-adjusted windows detects selection signatures associated with expression quantitative trait loci (eQTLs). BMC Genomics (2015) 0.78
Knowledge of Pharmacogenetics among Healthcare Professionals and Faculty Members of Health Training Institutions in Ghana. Ghana Med J (2015) 0.78
Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients. Br J Clin Pharmacol (2013) 0.76
Pharmacogenomics and migraine: possible implications. J Headache Pain (2008) 0.76
Use of contemporary genetics in cardiovascular diagnosis. Circulation (2014) 0.75
From Single Variants to Protein Cascades: MULTISCALE MODELING OF SINGLE NUCLEOTIDE VARIANT SETS IN GENETIC DISORDERS. J Biol Chem (2015) 0.75
ePGA: A Web-Based Information System for Translational Pharmacogenomics. PLoS One (2016) 0.75
Impact of germline and somatic missense variations on drug binding sites. Pharmacogenomics J (2016) 0.75
EHR based Genetic Testing Knowledge Base (iGTKB) Development. BMC Med Inform Decis Mak (2015) 0.75
Computational discovery of transcription factors associated with drug response. Pharmacogenomics J (2015) 0.75
Human genomic diversity, viral genomics and proteomics, as exemplified by human papillomaviruses and H5N1 influenza viruses. Hum Genomics (2009) 0.75
Improved candidate drug mining for Alzheimer's disease. Biomed Res Int (2014) 0.75
Exploring public genomics data for population pharmacogenomics. PLoS One (2017) 0.75
Predicting Amino Acid Substitution Probabilities Using Single Nucleotide Polymorphisms. Genetics (2017) 0.75
Natural variation in a single amino acid substitution underlies physiological responses to topoisomerase II poisons. PLoS Genet (2017) 0.75
Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters. Pharmacogenomics J (2016) 0.75
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med (2002) 27.55
The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy (2004) 13.16
Drug-induced prolongation of the QT interval. N Engl J Med (2004) 10.96
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med (1997) 10.02
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med (1989) 9.08
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med (2000) 8.32
Sudden cardiac death in the United States, 1989 to 1998. Circulation (2001) 7.92
Acute lymphoblastic leukemia. N Engl J Med (2004) 7.83
Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature (1998) 7.26
Allelic variation of human serotonin transporter gene expression. J Neurochem (1996) 7.08
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension (2004) 6.80
Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med (1993) 6.45
Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J (2001) 5.94
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol (2003) 5.51
Genomic screening and replication using the same data set in family-based association testing. Nat Genet (2005) 5.44
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol (2004) 5.06
Mammalian ABC transporters in health and disease. Annu Rev Biochem (2001) 4.90
Family-based designs in the age of large-scale gene-association studies. Nat Rev Genet (2006) 4.59
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation (2004) 4.56
Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA (2004) 4.47
Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med (1999) 4.45
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation (2003) 3.92
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84
The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch (2003) 3.76
Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev (2002) 3.73
A single Na(+) channel mutation causing both long-QT and Brugada syndromes. Circ Res (2000) 3.68
Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol (2002) 3.66
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat (2004) 3.40
CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet (2004) 3.32
Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am J Cardiol (2006) 2.94
Heterogeneity of therapeutic responses in asthma. Br Med Bull (2000) 2.86
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J (2002) 2.77
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest (1998) 2.62
Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther (2006) 2.49
The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics (2001) 2.29
CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther (2006) 2.21
Using the noninformative families in family-based association tests: a powerful new testing strategy. Am J Hum Genet (2003) 2.18
Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet (2004) 2.14
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res (2004) 2.10
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther (2003) 1.96
Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet (2005) 1.94
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation (2004) 1.94
Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry (2006) 1.89
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther (2006) 1.84
Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet (2003) 1.79
Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics (2003) 1.79
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res (1994) 1.72
Increased atrial fibrillation mortality: United States, 1980-1998. Am J Epidemiol (2002) 1.63
Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene (2006) 1.62
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res (2005) 1.62
Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med (2005) 1.58
Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost (2002) 1.58
Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell (2005) 1.58
Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood (2006) 1.52
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol (2004) 1.48
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood (2005) 1.42
Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res (2003) 1.37
TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci U S A (2004) 1.30
Functional genomics of membrane transporters in human populations. Genome Res (2005) 1.27
Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics (2005) 1.23
Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways. Hum Mol Genet (2005) 1.23
Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci U S A (1997) 1.23
Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc Natl Acad Sci U S A (2005) 1.20
Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol (1997) 1.20
WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension (2005) 1.18
Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics (2003) 1.12
CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol (1985) (2003) 1.11
Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics. Pharmacogenet Genomics (2006) 1.10
Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens (2003) 1.09
Polymorphism discovery in 51 chemotherapy pathway genes. Hum Mol Genet (2005) 1.09
Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide. Am J Hypertens (2005) 1.08
Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics J (2006) 1.08
C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension (2001) 1.07
MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther (2006) 1.06
Pharmacogenetics: inherited variation in amino acid sequence and altered protein quantity. Clin Pharmacol Ther (2004) 1.01
Lack of placebo effect on ambulatory blood pressure. Am J Hypertens (1995) 1.00
Genetic diversity and function in the human cytosolic sulfotransferases. Pharmacogenomics J (2006) 0.97
Comparative genomics analysis of human sequence variation in the UGT1A gene cluster. Pharmacogenomics J (2006) 0.97
Polymorphism screening in the cardiac K+ channel gene KCNA5. Clin Pharmacol Ther (2005) 0.94
Cloning and initial characterization of the human cardiac sodium channel (SCN5A) promoter. Cardiovasc Res (2004) 0.93
Aspirin resistance: a new independent predictor of vascular events? J Am Coll Cardiol (2003) 0.93
Human cardiac potassium channel DNA polymorphism modulates access to drug-binding site and causes drug resistance. J Clin Invest (2005) 0.93
DNA repair pathway profiling and microsatellite instability in colorectal cancer. Clin Cancer Res (2006) 0.92
Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic. Pharmacogenomics J (2004) 0.91
Discordant beta-blocker effects on clinic, ambulatory, resting, and exercise hemodynamics in patients with hypertension. Pharmacotherapy (2006) 0.91
Proarrhythmia as a pharmacogenomic entity: a critical review and formulation of a unifying hypothesis. Cardiovasc Res (2005) 0.87
Expression of drug pathway proteins is independent of tumour type. J Pathol (2006) 0.87
Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants. Psychiatr Genet (2006) 0.85
Mdr1 limits CYP3A metabolism in vivo. Mol Pharmacol (2000) 0.85
Missing value estimation methods for DNA microarrays. Bioinformatics (2001) 20.84
Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A (2001) 17.36
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
Boron nitride substrates for high-quality graphene electronics. Nat Nanotechnol (2010) 9.72
An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science (2001) 8.73
Linkage group I: the simultaneous estimation of recombination and interference. Birth Defects Orig Artic Ser (1976) 8.63
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
Factors associated with mortality in feedlot cattle: the Bruce County Beef Cattle Project. Can J Comp Med (1980) 7.74
Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages. Nature (1992) 7.66
Control of memory formation through regulated expression of a CaMKII transgene. Science (1996) 7.56
Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol (1995) 7.12
Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther (2012) 6.92
Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics (1996) 6.83
Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke (2001) 6.61
Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (2001) 6.36
Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med (1999) 6.21
Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J (2001) 5.94
Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol (1995) 5.86
Principal components analysis to summarize microarray experiments: application to sporulation time series. Pac Symp Biocomput (2000) 5.83
New Ballard Score, expanded to include extremely premature infants. J Pediatr (1991) 5.82
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med (1998) 5.65
The TAF(II)250 subunit of TFIID has histone acetyltransferase activity. Cell (1996) 5.20
Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol Cell Biol (1994) 5.13
Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med (2000) 5.12
Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered (2003) 5.06
Nicotine metabolism and intake in black and white smokers. JAMA (1998) 5.03
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation (2000) 4.80
Smokers of low-yield cigarettes do not consume less nicotine. N Engl J Med (1983) 4.80
A Vibrio cholerae pathogenicity island associated with epidemic and pandemic strains. Proc Natl Acad Sci U S A (1998) 4.75
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 4.67
Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1972) 4.64
Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke (2001) 4.64
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology (2002) 4.45
A dust-obscured massive maximum-starburst galaxy at a redshift of 6.34. Nature (2013) 4.43
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther (2011) 4.42
Factors associated with mortality and treatment costs in feedlot calves: the Bruce County Beef Project, years 1978, 1979, 1980. Can J Comp Med (1982) 4.34
Factors associated with morbidity and mortality in feedlot calves: the Bruce County beef project, year two. Can J Comp Med (1981) 4.17
Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med (1997) 4.13
An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene (2009) 4.10
Peptoids: a modular approach to drug discovery. Proc Natl Acad Sci U S A (1992) 4.08
Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther (2012) 4.05
Effect of mobile phone intervention for diabetes on glycaemic control: a meta-analysis. Diabet Med (2011) 4.04
Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin Pharmacol Ther (2012) 3.91
A bacteriophage encoding a pathogenicity island, a type-IV pilus and a phage receptor in cholera bacteria. Nature (1999) 3.89
The relationship of bone and blood lead to hypertension. The Normative Aging Study. JAMA (1996) 3.87
A curriculum for bioinformatics: the time is ripe. Bioinformatics (1998) 3.86
Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med (1998) 3.83
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation (1990) 3.83
Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med (1995) 3.77
Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. J Chromatogr (1981) 3.72
Hippocampal morphometry in schizophrenia by high dimensional brain mapping. Proc Natl Acad Sci U S A (1998) 3.72
Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet (1980) 3.71
Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res (2000) 3.70
A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA (1996) 3.69
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest (1998) 3.66
The diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones. Cell Mol Life Sci (2006) 3.62
Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int (1996) 3.62
Nomenclature for N-acetyltransferases. Pharmacogenetics (1995) 3.59
Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes. Mol Psychiatry (2009) 3.56
National character does not reflect mean personality trait levels in 49 cultures. Science (2005) 3.56
Is routine indwelling catheterisation of the bladder for caesarean section necessary? A systematic review. BJOG (2010) 3.54
Ballistic 2-d imaging through scattering walls using an ultrafast optical kerr gate. Science (1991) 3.53
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53
Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol (1995) 3.53
In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. Proc Natl Acad Sci U S A (1996) 3.53
Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther (2011) 3.50
Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature (1991) 3.48
Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association. Tob Control (1998) 3.47
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet (1990) 3.38
Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A (2000) 3.37
Association of CYP2C9*2 with bosentan-induced liver injury. Clin Pharmacol Ther (2013) 3.29
Infertility in male pesticide workers. Lancet (1977) 3.29
Cotinine disposition and effects. Clin Pharmacol Ther (1983) 3.26
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.25
Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly. Neuroimage (2005) 3.21
Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther (2012) 3.16
The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther (2012) 3.15
Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol (1998) 3.13
Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med (1995) 3.11
Relation of body mass index to asthma and atopy in children: the National Health and Nutrition Examination Study III. Thorax (2001) 3.10
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med (2000) 3.08
Suppression of melatonin secretion in some blind patients by exposure to bright light. N Engl J Med (1995) 3.08
Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA (1988) 3.04
The effect of maternal smoking during pregnancy on early infant lung function. Am Rev Respir Dis (1992) 3.01
Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS (1996) 2.95
BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell (2000) 2.94
The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther (2011) 2.93